Ascendis’ tangible NAV per share rose 11.7% from to 105 cents as at 31 December 2024. The Medical portfolio grew 16.5%, driven by strong performance and strategic acquisitions, while the larger Consumer portfolio edged up 1%.
Click here to read the SENS